Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.47
(-2.97%)
USD 1.47
(-2.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -88.48 Million USD | -1.81% |
| 2022 | -86.9 Million USD | 4.35% |
| 2021 | -90.86 Million USD | -78.11% |
| 2020 | -51.01 Million USD | 68.38% |
| 2019 | -161.35 Million USD | -21.56% |
| 2018 | -132.73 Million USD | -93.71% |
| 2017 | -68.52 Million USD | -42.52% |
| 2016 | -48.07 Million USD | -133.81% |
| 2015 | -20.56 Million USD | -94.52% |
| 2014 | -10.57 Million USD | -51.53% |
| 2013 | -6.97 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -16.94 Million USD | -1036.22% |
| 2024 Q2 | -10.98 Million USD | 35.15% |
| 2023 Q3 | -29.26 Million USD | 1.04% |
| 2023 Q1 | -28.16 Million USD | -1.9% |
| 2023 FY | -88.48 Million USD | -1.81% |
| 2023 Q2 | -29.56 Million USD | -5.0% |
| 2023 Q4 | -1.49 Million USD | 94.9% |
| 2022 Q2 | -20.53 Million USD | -9.28% |
| 2022 FY | -86.9 Million USD | 4.35% |
| 2022 Q4 | -27.63 Million USD | -38.51% |
| 2022 Q3 | -19.95 Million USD | 2.82% |
| 2022 Q1 | -18.78 Million USD | 17.61% |
| 2021 Q2 | -18.16 Million USD | 36.84% |
| 2021 Q1 | -28.75 Million USD | -111.47% |
| 2021 Q3 | -21.14 Million USD | -16.44% |
| 2021 Q4 | -22.8 Million USD | -7.84% |
| 2021 FY | -90.86 Million USD | -78.11% |
| 2020 Q1 | -15.32 Million USD | 21.18% |
| 2020 FY | -51.01 Million USD | 68.38% |
| 2020 Q2 | -11.57 Million USD | 24.52% |
| 2020 Q3 | -10.65 Million USD | 7.87% |
| 2020 Q4 | -13.59 Million USD | -27.56% |
| 2019 Q3 | -23.13 Million USD | 47.03% |
| 2019 Q1 | -27.28 Million USD | -15.81% |
| 2019 FY | -161.35 Million USD | -21.56% |
| 2019 Q4 | -19.44 Million USD | 15.95% |
| 2019 Q2 | -43.68 Million USD | -60.13% |
| 2018 Q4 | -23.55 Million USD | -14.18% |
| 2018 FY | -132.73 Million USD | -93.71% |
| 2018 Q3 | -20.63 Million USD | -168.44% |
| 2018 Q1 | -30.22 Million USD | -31.81% |
| 2018 Q2 | -7.68 Million USD | 74.57% |
| 2017 Q1 | -12.55 Million USD | -9.45% |
| 2017 Q2 | -14.83 Million USD | -18.15% |
| 2017 Q3 | -18.19 Million USD | -22.6% |
| 2017 Q4 | -22.93 Million USD | -26.07% |
| 2017 FY | -68.52 Million USD | -42.52% |
| 2016 FY | -48.07 Million USD | -133.81% |
| 2016 Q4 | -11.47 Million USD | -7.3% |
| 2016 Q3 | -10.69 Million USD | 16.91% |
| 2016 Q2 | -12.87 Million USD | 1.29% |
| 2016 Q1 | -13.03 Million USD | -164.64% |
| 2015 Q1 | -3.28 Million USD | -0.71% |
| 2015 FY | -20.56 Million USD | -94.52% |
| 2015 Q3 | -11.65 Million USD | -256.33% |
| 2015 Q4 | -4.92 Million USD | 57.72% |
| 2015 Q2 | -3.27 Million USD | 0.3% |
| 2014 Q4 | -3.25 Million USD | -3.86% |
| 2014 Q1 | -2.08 Million USD | 0.0% |
| 2014 Q2 | -2.08 Million USD | 0.0% |
| 2014 Q3 | -3.13 Million USD | -50.16% |
| 2014 FY | -10.57 Million USD | -51.53% |
| 2013 FY | -6.97 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 71.317% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 74.87% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 41.629% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 67.956% |
| bluebird bio, Inc. | -211.91 Million USD | 58.247% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 25.341% |
| Imunon, Inc. | -19.51 Million USD | -353.4% |
| Editas Medicine, Inc. | -153.21 Million USD | 42.252% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 106.516% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 111.217% |
| Myriad Genetics, Inc. | -112 Million USD | 20.999% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 135.435% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 6823.48% |
| Verastem, Inc. | -87.36 Million USD | -1.275% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.975% |
| Waters Corporation | 642.23 Million USD | 113.777% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.476% |
| Biogen Inc. | 1.16 Billion USD | 107.62% |
| Nektar Therapeutics | -276.05 Million USD | 67.948% |
| Perrigo Company plc | -12.7 Million USD | -596.701% |
| Dynavax Technologies Corporation | -6.38 Million USD | -1284.896% |
| Illumina, Inc. | -1.16 Billion USD | 92.379% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -98.373% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 80.074% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 19.969% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -121.979% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 152.779% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 65.683% |
| Evolus, Inc. | -61.68 Million USD | -43.44% |
| Adicet Bio, Inc. | -142.65 Million USD | 37.977% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.238% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 57.715% |
| FibroGen, Inc. | -284.23 Million USD | 68.87% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 107.136% |
| OPKO Health, Inc. | -188.86 Million USD | 53.151% |
| Homology Medicines, Inc. | -53.74 Million USD | -64.637% |
| Geron Corporation | -184.12 Million USD | 51.946% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 79.902% |
| Exelixis, Inc. | 207.76 Million USD | 142.587% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -3.011% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -86.256% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 81.612% |
| Zoetis Inc. | 2.34 Billion USD | 103.775% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 63.015% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -63.285% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 102.444% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -109.676% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 75.844% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 83.492% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 183.363% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 131.421% |
| Blueprint Medicines Corporation | -506.98 Million USD | 82.548% |
| Insmed Incorporated | -749.56 Million USD | 88.196% |
| TG Therapeutics, Inc. | 12.67 Million USD | 798.24% |
| Incyte Corporation | 597.59 Million USD | 114.806% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 88.365% |